Brien et al. reported that targeted degradation of BRD9, a component of the SWI/SNF complex found in synovial sarcoma, can inhibit tumor progression [31], which lays the foundation for clinical trials of the BRD9 degraders FHD-609 (NCT04965753) and CFT8634 (NCT05355753) (Figure 3) in SS; however, they were terminated owing to a lack of sufficient efficacy as single agents. Here, SMARCA1 is linked to synovial sarcoma.